Pfizer Tests The Luck Of The Irish; Will The US Let Its Pharma Pot Of Gold Go?
Pfizer and Allergan confirmed they are in friendly merger negotiations. Now the question is if Pfizer can afford to pay for Allergan and will the US government let a pharma giant the size of Pfizer go without a fight.
You may also be interested in...
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Priya Singhal took over as Biogen's top R&D leader on an interim basis after Al Sandrock’s unexpected retirement. "I understand that this is a challenging time," she told Scrip.
The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.